DOCSLIB.ORG

Event – Actelion Hoping New Data Will Build on Tracleer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Event – Actelion Hoping New Data Will Build on Tracleer January 13, 2010 Event – Actelion hoping new data will build on Tracleer Amy Brown Actelion is fast approaching the release of pivotal results from a trial of its biggest product, Tracleer, in a new indication, idiopathic pulmonary fibrosis (IPF). Data due this quarter could have a considerable impact on the future of the product, and the company as a whole. Unfortunately, hopes for a successful outcome are not particularly high; some analysts are giving the trial a 50% chance of success, others even lower. These low expectations should shield the stock from substantial declines should the news be bad. However, with some predicting that a positive read out has the potential to double Actelion’s group revenue, good news will almost certainly prompt a jump in the Swiss company’s share price. Product Name Tracleer Company Actelion Product NPV SFr3.78bn * Mkt Cap SFr7.25bn * %of Mkt Cap 53% Event Summary Phase III data Expected Decision Q1, 2010 Could also impact Gilead (Letairis/ambrisentan) *as of 12/01/2010 Lung function Tracleer, generically known as bosentan, is an oral dual endothelin receptor antagonist. Concentrations of the protein endothelin, which has potent vasoconstriction properties and is known to promote fibrosis and inflammation, are elevated in interstitial lung disease, hence the use and investigation of this drug in this area. IPF is characterised by scarring of the lung; air sacs gradually become replaced by fibrotic tissue which irreversibly impedes their ability to transfer oxygen to the bloodstream. Nothing is yet approved to treat the condition, outside of Japan. Tracleer is already on the market as a treatment for pulmonary arterial hypertension, a condition where the arteries connecting the lung and heart are restricted, causing damage to the organs and reducing life expectancy. It is also used as a treatment for digital ulcers resulting from scleroderma. The product currently accounts for the majority of the company’s revenues, and by 2014 will still be generating 80% of its top line. Sales are on track to reach €1.50bn ($1.39bn) this year, and the consensus forecast for 2014 currently sits at €2.18bn. With hopes for success in IPF low, these forecasts are unlikely to include much of a contribution from sales in this use. It could potentially be a large market though; analysts at Raymond James believe that should the drug be approved in the US, Europe and Japan, sales in IPF alone could reach €1.64bn by 2015, whilst Morgan Stanley has penciled in peak sales of €1.20bn that year. As such, the potential for big upgrades to consensus should Build-3 be positive is clear. Glimmers of hope? The main reason for concern about the outcome of the study is that many products have tried and failed to show any efficacy in treating IPF. Over the last few years Novartis’ Gleevec, Wyeth’s Enbrel, Biogen Idec’s Avonex and MondoBiotech’s Actimmune were all tested but ultimately scrapped in this setting. Build-3 enrolled more than 600 patients with early, biopsy-confirmed IPF. The primary endpoint is, however, fairly tough; the company is trying to demonstrate that Tracleer delays disease worsening or death in patients. However, there are a number of reasons why some see glimmers of hope. Firstly, the trial has already passed two independent data safety monitoring board assessments for safety and futility, raising hopes that the data will at least point towards efficacy, if not establish it statistically. Plus, in 2008 Actelion increased enrolment from 390 to 600 subjects, which could possibly suggest that doctors were willing to enroll their patients in the trials, some analysts believe. Additionally, a previous phase II trial called Build-1, whilst failing to improve walking ability, showed positive trends relating to mortality and morbidity in a subset of IPF patients with earlier stage disease. Because the patients recruited in Build-3 did not have very advanced disease, they too could prove more receptive to drug treatment. Eagerly awaited Still, a lot of this evidence is circumstantial, and analysts at best remain very cautious. The upside is clear though; should the trial be positive the lack of any available treatments for lung fibrosis is likely to mean off- label will ramp up very quickly, prior to any regulatory approvals. This outcome would not only cause Actelion’s share price jump, sales and earnings could well be given a boost as early as this year. This would be very useful for the company, as the ongoing and expensive clinical programme for insomnia drug, almorexant, partnered with GlaxoSmithKline is going to drag on margins for some time. A negative outcome, whilst not entirely unexpected, would certainly be disappointing, as it would remove a significant sales growth driver and pile pressure onto the remainder of the pipeline, which is also viewed as largely high risk. As such, with the potential to significantly impact Actelion’s share price, sales and earnings, the results from the Build-3 study are eagerly awaited. More from Evaluate Vantage Evaluate HQ 44-(0)20-7377-0800 Evaluate Americas +1-617-573-9450 Evaluate APAC +81-(0)80-1164-4754 © Copyright 2021 Evaluate Ltd..
Load more

Recommended publications
  • 204569Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204569Orig1s000 MEDICAL REVIEW(S) Cross Discipline Team Leader Review 3. CMC/Device Dr. Khairuzzaman found the drug product portion of the NDA to be acceptable, and without need for phase 4 commitments. Dr. Sapru’s review stated that with the exception of a pending issue concerning the control of potential genotoxic impurity (b) (4) the NDA was approvable in terms of drug substance. Dr. Suarez found that the NDA was acceptable from a biopharmaceutics perspective. The Office of Compliance issuance of an acceptable recommendation for drug substance manufacturing and testing facilities was pending at the time of this review. 4. Nonclinical Pharmacology/Toxicology Dr. Richard Siarey completed the primary nonclinical review, and Dr. Lois Freed completed a supervisory memo. Dr. Siarey’s overall conclusion was that from a nonclinical perspective, approval of the suvorexant NDA was recommended. However, he found evidence that catapelxy was observed in dogs exposed to MK-4305 (suvorexant) near Tmax, although he concluded that additional information could have been gained by studying the drug in an experimental model that has been used for diagnosing cataplexy in dogs. Dr. Siarey suggested that since cataplexy occurred in dogs near Tmax, a time at which if used for insomnia patients would ordinarily be in bed, safety concern for humans was reduced. Dr. Siarey also found that the neurobehavioral assessment in the pre- and post-natal developmental study was not complete, as the passive avoidance tests was performed too early in development, while learning/acquisition tests and retention/memory tests were not conducted.
    [Show full text]
  • Anti-Infectives Industry Over the Next 5 Years and Beyond
    Bridging the innovation gap... New Drug Futures: Products that could change the pharma market to 2013 and beyond Over 70 pipeline prospects This new major and insightful 450 page in 8 major therapy areas analysis evaluates, compares and contrasts the are analysed in this report prospects for the development compounds that could revolutionise the pharmaceutical Anti-infectives industry over the next 5 years and beyond. Cardiovascular CNS The report provides: Gastrointestinal Detailed background and market context for Metabolic each therapy area covered: Musculoskeletal Addressable patient population Oncology Current treatments Sales drivers Respiratory Sales breakers Future treatments Market dynamics – winners and losers Key drug launches by 2013 Unique sales forecasts by major product to 2013 Over 70 key products assessed Unique evaluation scores for key areas such as novelty of mechanism, clinical data and competition Critical and detailed appraisal of each product‟s research and development Extensive pipeline listings, putting the profiled products into their competitive context The search – and need – for new products has never been greater and what’s in the development pipeline has never generated more interest. That is why this analysis is so important! GLOBAL PHARMA MARKET IN CONTEXT THE Are there too many prophets of doom ready to write-off the research-based pharma industry in the future? Too few novel There is plenty on which to base such anxiety. The research-based industry products and an must achieve a fair price in the face of greater cost control, while the aggressive generic burden of regulation is setting the bar high for successful product sector are taking introduction.
    [Show full text]
  • The Dual Orexin Receptor Antagonist TCS1102 Does Not Affect Reinstatement of Nicotine- Seeking
    RESEARCH ARTICLE The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine- seeking Shaun Yon-Seng Khoo, Gavan P. McNally, Kelly J. Clemens* School of Psychology, University of New South Wales, Sydney, Australia * [email protected] a1111111111 a1111111111 a1111111111 Abstract a1111111111 a1111111111 The orexin/hypocretin system is important for appetitive motivation towards multiple drugs of abuse, including nicotine. Both OX1 and OX2 receptors individually have been shown to influence nicotine self-administration and reinstatement. Due to the increasing clinical use of dual orexin receptor antagonists in the treatment of disorders such as insomnia, we OPEN ACCESS examined whether a dual orexin receptor antagonist may also be effective in reducing nico- Citation: Khoo SY-S, McNally GP, Clemens KJ tine seeking. We tested the effect of intracerebroventricular (i.c.v.) administration of the (2017) The dual orexin receptor antagonist potent and selective dual orexin receptor antagonist TCS1102 on orexin-A-induced food TCS1102 does not affect reinstatement of nicotine- self-administration, nicotine self-administration and reinstatement of nicotine-seeking in seeking. PLoS ONE 12(3): e0173967. https://doi. org/10.1371/journal.pone.0173967 rats. Our results show that 30 μg of TCS1102 i.c.v. abolishes orexin-A-induced increases in food self-administration but does not reduce nicotine self-administration. Neither i.c.v. 10 μg Editor: Judith Homberg, Radboud University Medical Centre, NETHERLANDS nor 30 μg of TCS1102 reduced compound reinstatement after short-term (15 days) self- administration nicotine, but 30 μg transiently reduced cue/nicotine compound reinstatement Received: November 24, 2016 after chronic self-administration (29 days).
    [Show full text]
  • Annual HFHS Publications List 2017 This Bibliography Aims to Recognize
    Annual HFHS Publications List 2017 This bibliography aims to recognize the scholarly activity and provide ease of access to journal articles, meeting abstracts, book chapters, books and other works published by Henry Ford Health System personnel. Searches were conducted in PubMed, Embase, Web of Science, and Google Scholar during 2017, and then imported into EndNote for formatting. The searches captured over 1,500 unique publications from Henry Ford Health System authors for 2017. Click the “Full Text” link to view the articles to which Sladen Library provides access. If the full-text of the article is not available, you may request it through ILLiad by clicking on the “Article Request Form,” or by calling us at 313-916-2550. If you would like to be added to the monthly email distribution list to automatically receive a PDF of this bibliography in your inbox, or you have any questions or comments, please contact Angela Cabrera at [email protected]. Administration Omar J, Heidemann DL, Blum-Alexandar B, Uju-Eke C, Alam Z, Willens DE, and Wisdom K. Fresh prescription: Improving nutrition education and access to fresh produce in Detroit J Gen Intern Med 2017; 32(2):S752. PMID: Not assigned. Abstract Administration Smith KL, Fedel P, and Heitman J. Incapacitated surrogates: A new and increasing dilemma in hospital care J Clin Ethics 2017; 28(4):279-289. PMID: 29257763. Article Request Form Allergy Brown KR, Krouse RZ, Calatroni A, Visness CM, Sivaprasad U, Kercsmar CM, Matsui EC, West JB, Makhija MM, Gill MA, Kim H, Kattan M, Pillai D, Gern JE, Busse WW, Togias A, Liu AH, and Khurana Hershey GK.
    [Show full text]
  • 2017 Research Annual Report Table of Contents Summaries of 2017
    2017 RESEARCH ANNUAL REPORT TABLE OF CONTENTS SUMMARIES OF 2017 NATIONAL INSTITUTES OF HEALTH AND OTHER FEDERAL GRANTS AWARDED TO HFHS PART I – INTERNAL MEDICINE DEPARTMENT_________________________________ ALLERGY AND IMMUNOLOGY ................................................................................................. 1 CARDIOLOGY/CARDIOVASCULAR RESEARCH…………………………………………….1 ENDOCRINOLOGY AND METABOLISM .................................................................................. 2 GASTROENTEROLOGY ............................................................................................................. .3 HEMATOLOGY/ONCOLOGY…………………………………………………………………...4 HYPERTENSION AND VASCULAR RESEARCH……………………………………………...5 INFECTIOUS DISEASE…………………………………………………………………………..9 PULMONARY……………………………………………………………………………………10 SLEEP MEDICINE ....................................................................................................................... 11 GENERAL INTERNAL MEDICINE…………………………………………………………….13 PART II – ALL OTHER CLINICAL DEPARTMENTS_______________________________ DERMATOLOGY ........................................................................................................................ 14 NEUROLOGY .............................................................................................................................. 15 NEUROSURGERY……………………………………………………………………………….23 ORTHOPAEDICS/BONE & JOINT……………………………………………………………..24 PATHOLOGY ..............................................................................................................................
    [Show full text]
  • Study Protocol
    Confidential Page 1 Protocol No. Everolimus Investigator-initiated Protocol Template RAD001 (Everolimus) Clinical evaluation of everolimus (a rapamycin analog) in restoring salivary gland function to patients treated with radiotherapy for head and neck cancer CRAD001XUS274T Authors: Panayiotis Savvides, MD PhD MPH (Principal Investigator) Kirsten Limesand, PhD (co-Investigator) Denise Roe, DrPH (co-Investigator) Sun Yi, MD (co-Investigator) Julie Bauman, MD (co-Investigator) Daruka Mahadevan, MD PhD (co-Investigator) Version number: 1.2 Release date 06/22/2018 Referenced Investigator Brochure 15, release date 27-April-2016 Edition IRB NUMBER: PHXB-17-0072-70-15 IRB APPROVAL DATE: 07/03/2018 Confidential Page 2 Protocol No. Table of contents Table of contents..................................................................................................................2 List of figures.......................................................................................................................3 List of tables.........................................................................................................................3 List of abbreviations ............................................................................................................4 Glossary of terms.................................................................................................................6 Schema.................................................................................................................................8 1
    [Show full text]
  • Understanding Peptide Binding in Class a G Protein-Coupled Receptors
    Molecular Pharmacology Fast Forward. Published on July 10, 2019 as DOI: 10.1124/mol.119.115915 This article has not been copyedited and formatted. The final version may differ from this version. MOL# 115915 Understanding peptide binding in Class A G protein-coupled receptors Irina G. Tikhonova, Veronique Gigoux, Daniel Fourmy School of Pharmacy, Medical Biology Centre, Queen’s University Belfast, Belfast BT9 7BL, Northern Ireland, United Kingdom, (I.G.T.) INSERM ERL1226-Receptology and Therapeutic Targeting of Cancers, Laboratoire de Physique et Chimie des Nano-Objets, CNRS UMR5215-INSA, Université de Toulouse III, F- 31432 Toulouse, France. (V.G., D.F.) Downloaded from molpharm.aspetjournals.org Keywords: peptides, peptide GPCRs, peptide binding at ASPET Journals on September 30, 2021 1 Molecular Pharmacology Fast Forward. Published on July 10, 2019 as DOI: 10.1124/mol.119.115915 This article has not been copyedited and formatted. The final version may differ from this version. MOL# 115915 Running title page: Peptide Class A GPCRs Corresponding author: Irina G. Tikhonova School of Pharmacy, Medical Biology Centre, 97 Lisburn Road, Queen’s University Belfast, Belfast BT9 7BL, Northern Ireland, United Kingdom Email: [email protected] Tel: +44 (0)28 9097 2202 Downloaded from Number of text pages: 10 Number of figures: 3 molpharm.aspetjournals.org Number of references: 118 Number of tables: 2 Words in Abstract: 163 Words in Introduction: 503 Words in Concluding Remarks: 661 at ASPET Journals on September 30, 2021 ABBREVIATIONS: AT1,
    [Show full text]
  • Annual Report 2007 in Detail
    Annual Report 2007 In Detail WorldReginfo - 954f6161-6bac-48a4-873f-6ee9f4f1d49c Content WorldReginfo - 954f6161-6bac-48a4-873f-6ee9f4f1d49c 01 Marketed Products 04 Summary of Achievements 05 Tracleer® 06 Ventavis® 08 Zavesca® 08 02 Research & Development 10 Drug Discovery 11 Drug Discovery Platforms 11 Therapeutic Areas 12 Clinical Development 18 03 Our Strategy 27 04 Business Development 29 05 Financial Report 32 Corporate Governance 37 Consolidated Financial Statements 49 Holding Company Statements 78 03 WorldReginfo - 954f6161-6bac-48a4-873f-6ee9f4f1d49c 01 Marketed Products WorldReginfo - 954f6161-6bac-48a4-873f-6ee9f4f1d49c Summary of achievements Actelion’s strong commitment to expand Tracleer® into new indications is demonstrated by the comprehensive clini- Actelion continued its strong performance in 2007 and further cal trial program, including the COMPASS trials (combina- built its leadership position in pulmonary arterial hypertension tion therapy), BUILD 3 (idiopathic pulmonary fibrosis) and (PAH) with Tracleer® (bosentan) sales of CHF 1,18 billion, a FUTURE (pediatric indication). growth of 31% compared to the previous year (+32% in lo- cal currencies). This strong performance was seen in all re- Several marketing and life cycle activities were initiated for gions worldwide, including the United States, Europe, and Ventavis® in 2007 to enhance its profile and set it up for con- Japan in particular. It was also the first full year of marketing tinued success in 2008. Ventavis® (iloprost) after the acquisition of CoTherix in the United States. In an increasingly competitive PAH market, Zavesca® (miglustat), Actelion’s second global brand, gener- Ventavis® was able to contribute CHF 78.2 million to our PAH ated sales of CHF 35.3 million, a growth of 39% compared franchise revenues.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
    INN Working Document 18.435 31/05/2018 Addendum1 to "The use of stems in the selection of International Nonproprietary names (INN) for pharmaceutical substances" WHO/EMP/RHT/TSN/2013.1 Programme on International Nonproprietary Names (INN) Technologies Standards and Norms (TSN) Regulation of Medicines and other health technologies (RHT) World Health Organization, Geneva © World Health Organization 2018 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme. This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization. Addendum1 to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/RHT/TSN/2013.1 1 This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" 2013. ------------------------------------------------------------------------------------------------------------ -apt- aptamers, classical and mirror ones (a) avacincaptad pegol (113), egaptivon pegol (111), emapticap pegol (108), lexaptepid pegol (108), olaptesed pegol (109), pegaptanib (88) (b) -vaptan stem: balovaptan (116), conivaptan
    [Show full text]
  • A Multicentre Phase II Study of AZD1775 Plus Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
    Clinical Study Protocol AstraZeneca AZD1775 - D6010C00004 Version 10, 05 September 2018 Clinical Study Protocol Drug Substance AZD1775 Study Code D6010C00004 Version 10 Date 05 September 2018 A Multicentre Phase II Study of AZD1775 plus Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Sponsor: AstraZeneca AB, 151 85 Södertälje, Sweden. EudraCT: 2015-000886-30 CONFIDENTIAL AND PROPRIETARY 1 of 153 Clinical Study Protocol AstraZeneca AZD1775 - D6010C00004 Version 10, 05 September 2018 VERSION HISTORY Version 10.0, 05 September 2018 (Amendment 9) Changes to the protocol are summarised below: ! Specified that patients still receiving AZD1775 after the primary data cut-off will have a Final Protocol Visit (FPV) occurring at their next scheduled visit focused on capturing safety information. Following the FPV, patients may continue to receive treatment with AZD1775 ± chemotherapy as deemed appropriate by the Investigator (see Table 2, footnote ‘bb’, Table 3, footnote ‘cc’, and Section 4.4). The end-of-study treatment visit is not required for patients continuing treatment after the FPV. ! Amended Section 5.6 to add clarification about optional tumour biopsies. ! Clarified that blood samples and optional tumour biopsies for exploratory biomarker research will be collected at treatment discontinuation due to disease progression for subjects that continue taking AZD1775 ± chemotherapy after the FPV (see Section 5.6). ! Clarified how SAEs will be reported after the FPV (see Section 6.4.1 and Section 6.5). ! Clarified that after the FPV pregnancies will be monitored while patients are on treatment and for 30 days after their final dose of AZD1775 ±chemotherapy (Section 6.7).
    [Show full text]
  • Nonpublication of Trial Results for New Neurological Drugs: a Systematic Review
    Nonpublication of Trial Results for New Neurological Drugs: A Systematic Review NOTE: This is an earlier version of the manuscript published in Annals of Neurology 2017. It contains information and data that editors/referees asked us to remove as a condition for acceptance. We strongly disagreed and therefore present those data in this version. Amanda K Hakala1, BSc, Dean Fergusson2, PhD, Jonathan Kimmelman1*, PhD 1 Studies of Translation, Ethics, and Medicine (STREAM), Biomedical Ethics Unit, McGill University, H3A 1X1, Montreal, Canada 2 Centre for Practice Changing Research, Ottawa Hospital Research Institute, University of Ottawa, K1H 8L6, Ottawa, Canada Corresponding author: Jonathan Kimmelman [email protected] (514) 398-3306 Abstract word count: 236 Introduction word count: 302 Discussion word count: 885 Total manuscript body word count: 2996 Number of figures: 3 Number of tables: 3 1 ABSTRACT Objective: To evaluate nonpublication rates among trials of new successful and unsuccessful neurological drugs. Methods: Our ‘licensed’ drug cohort consisted of all novel drugs receiving FDA licensure 2005 to 2012 inclusive in seven neurological disorders. Our cohort of ‘stalled’ drugs included all experimental agents tested in the same domains that had at least one completed phase III trial in the same timeframe but failed to receive FDA approval. Trials of these drugs were included in our sample if their primary outcome collection occurred before October 1, 2010. We determined the publication status of eligible trials using searches of clinicaltrials.gov, Google Scholar, PubMed, Embase, sponsor websites, and direct electronic query of trial contacts and sponsors. The primary outcome was journal publication (or results reporting in other media).
    [Show full text]
  • WO 2017/151816 Al 8 September 2017 (08.09.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/151816 Al 8 September 2017 (08.09.2017) P O P C T (51) International Patent Classification: Gilead Apollo, LLC, 333 Lakeside Drive, Foster City, C07D 495/04 (2006.01) A61P 3/00 (2006.01) California 94404 (US). YANG, Xiaowei; c/o Gilead A61K 31/519 (2006.01) A61P 3/06 (2006.01) Apollo, LLC, 333 Lakeside Drive, Foster City, California 94404 (US). (21) International Application Number: PCT/US20 17/020271 (74) Agents: TANNER, Lorna L. et al; Sheppard Mullin Richter & Hampton LLP, 379 Lytton Avenue, Palo Alto, (22) Date: International Filing California 94301-1479 (US). 1 March 2017 (01 .03.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (30) Priority Data: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 62/302,755 2 March 2016 (02.03.2016) US HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 62/303,237 3 March 2016 (03.03.2016) US KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (71) Applicant: GILEAD APOLLO, LLC [US/US]; 333 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, Lakeside Drive, Foster City, California 94404 (US).
    [Show full text]